Soleus Capital Management, L.P. Iveric Bio, Inc. Transaction History

Soleus Capital Management, L.P.

$1.18 Billion
Q3 2024

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$18.67 - $24.56 $229,921 - $302,456	12,315 Added 0.58%	2,127,043 $51.8 Million
Q4 2022 Feb 14, 2023	SELL	$17.24 - $23.95 $6.69 Million - $9.29 Million	-387,873 Reduced 15.5%	2,114,728 $45.3 Million
Q3 2022 Nov 14, 2022	BUY	$9.4 - $18.59 $14.9 Million - $29.5 Million	1,588,255 Added 173.7%	2,502,601 $44.9 Million
Q2 2022 Aug 15, 2022	SELL	$9.12 - $18.9 $457,185 - $947,456	-50,130 Reduced 5.2%	914,346 $8.8 Million
Q1 2022 May 16, 2022	SELL	$12.15 - $16.83 $1.26 Million - $1.75 Million	-103,900 Reduced 9.73%	964,476 $16.2 Million
Q4 2021 Feb 14, 2022	SELL	$13.83 - $18.78 $340,826 - $462,814	-24,644 Reduced 2.25%	1,068,376 $17.9 Million
Q3 2021 Nov 15, 2021	SELL	$7.07 - $17.5 $12.1 Million - $30 Million	-1,715,323 Reduced 61.08%	1,093,020 $17.8 Million
Q2 2021 Aug 16, 2021	SELL	$5.69 - $7.17 $3.26 Million - $4.11 Million	-572,636 Reduced 16.94%	2,808,343 $17.7 Million
Q1 2021 May 17, 2021	BUY	$5.08 - $6.89 $9.06 Million - $12.3 Million	1,783,700 Added 111.67%	3,380,979 $20.9 Million
Q4 2020 Feb 16, 2021	SELL	$5.65 - $7.66 $500,590 - $678,676	-88,600 Reduced 5.26%	1,597,279 $11 Million
Q3 2020 Nov 13, 2020	BUY	$4.01 - $6.29 $237,303 - $372,229	59,178 Added 3.64%	1,685,879 $9.51 Million
Q2 2020 Aug 14, 2020	BUY	$3.06 - $6.6 $59,816 - $129,016	19,548 Added 1.22%	1,626,701 $8.3 Million
Q1 2020 May 15, 2020	BUY	$2.83 - $8.44 $2.66 Million - $7.92 Million	938,782 Added 140.46%	1,607,153 $5.53 Million
Q4 2019 Feb 14, 2020	BUY	$0.93 - $8.58 $621,585 - $5.73 Million	668,371 New	668,371 $5.73 Million

Others Institutions Holding ISEE

# of Institutions

Shares Held

250K

Call Options Held

40K

Put Options Held

View Full List

About IVERIC bio, Inc.

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

More about ISEE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Soleus Capital Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Soleus Capital Management, L.P. with notifications on news.

Account